L26/P-915 Combined Autologous Stem Cells and Platelet-Rich Plasma for Endometrial Regeneration in Refractory Thin Endometrium and Asherman’s Syndrome: A Pilot Study
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.1239 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von N. Malhotra und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Can combined autologous stem cells and Platelet Rich Plasma improve endometrial and menstrual functions in women with refractory thin endometrium or Asherman’s syndrome? Summary answer Autologous stem cells and PRP, in combination, is safe and efficacious in improving endometrial thickness and menstrual symptoms. What is known already Refractory thin endometrium and Asherman’s syndrome cause amenorrhea and infertility. Standard treatments including hysteroscopic adhesiolysis and estrogen therapy may fail to restore optimal endometrial function. In infertile women surrogacy is the last option, with limited acceptance and availability. Regenerative therapy, including autologous stem cell therapy and PRP, have shown promise in such cases. Regeneration of endometrium is achieved through angiogenesis, cellular proliferation, and tissue repair. The study was based on the hypothesis that combination of autologous stem cells and PRP may work synergistic to compound benefits, compared to individual therapy. Study design, size, duration In a prospective, three-arm pilot study conducted on thirty women with refractory thin endometrium or Asherman’s syndrome, autologous stem cells, PRP and combination were compared for safety and efficacy, when administered sub-endometrial. Outcomes including improvement in symptoms and endometrial thickness(ET) were assessed over six months post-intervention. Further correlation of outcomes was done with growth factor expression. The study was conducted over 2 years (February 2024 to January 2026). Participants/materials, setting, methods Women aged 21 to 40 years, suffering hypo/amenorrhea, with ET < 5 mm or Asherman’s syndrome (n = 30) were allocated to receive either Autologous bone marrow-derived stem cells, PRP, or combination. Administration was sub-endometrial under hysteroscopic guidance during proliferative phase. Those with genital Tuberculosis in past were excluded. Bone marrow mononuclear cells and PRP was prepared and characterized and further assessed for growth factors including VEGF, PDGF, EGF, IGF, and FGF. Main results and the role of chance The mean age of subjects was 31.36 ± 3.85 years, and baseline ET being 4.28 ± 0.61 mm. Menstrual functions improved in 76% (23/30) women, which was numerically higher in PRP and combination therapy (80%), compared to stem cells (50%) although not significant (p = 0.24). A significant increase in ET [ 5.34 ± 1.24 mm (P < 0.0005)], was observed, which was maximum at 3.2 (±0.3) months in all arms. Time-to-ET max suggested earlier attainment in combination therapy group compared to monotherapy. Mean ET increased maximally in combination arm, [1.62 ± 1.02 mm (P < 0.005)], compared to PRP ([1.04 ± 0.58 mm [P < 0.05)], and stem cell [1.07 ± 0.70 mm (P < 0.05)]. Growth factor analysis revealed higher concentrations of angiogenic and proliferative mediators, including VEGF, PDGF, EGF, IGF, and FGF, in PRP-containing group. There was positive correlation between ET max and key growth factors, VEGF and PDGF, suggesting a paracrine-driven regenerative response. Improvement in menstrual function correlated with ET improvement and growth factor expression. Bone marrow-derived mononuclear cells demonstrated high viability (>99%) with appropriate marker expression. There were no adverse effects in either group Limitations, reasons for caution The study had a small sample size, and lacked randomization. Reproductive outcomes including implantation and pregnancy rates were not evaluated, limiting conclusions on fertility success. Wider implications of the findings There is potential of regenerative therapy for women with hypo/amenorrhea, given limited options after successful adhesiolysis. Combining PRP with stem cell may represent a novel therapeutic option, warranting validation through larger trials. Trial registration number Yes
Zitieren
APA
Malhotra, N., Bharti, J., Mohanty, S., Pnadey, H., Agarwal, M., Sharma, A., Mendiratta, M., & Das, J. (2026). L26/P-915 Combined Autologous Stem Cells and Platelet-Rich Plasma for Endometrial Regeneration in Refractory Thin Endometrium and Asherman’s Syndrome: A Pilot Study. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1239
Vancouver
Malhotra N, Bharti J, Mohanty S, Pnadey H, Agarwal M, Sharma A, et al. L26/P-915 Combined Autologous Stem Cells and Platelet-Rich Plasma for Endometrial Regeneration in Refractory Thin Endometrium and Asherman’s Syndrome: A Pilot Study. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1239
BibTeX
@article{Malhotra2026,
author = {Malhotra, N. and Bharti, J. and Mohanty, S. and Pnadey, H.C. and Agarwal, M. and Sharma, A. and Mendiratta, M. and Das, J.},
title = {L26/P-915 Combined Autologous Stem Cells and Platelet-Rich Plasma for Endometrial Regeneration in Refractory Thin Endometrium and Asherman’s Syndrome: A Pilot Study},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.1239}
}
EUVIMED